The overall goal of this proposal is to investigate the molecular and cellular biology of brain tumors and to link and integrate these efforts with clinical studies that are designed to optimize diagnosis, prognosis and treatment in infants, children, and adults with these neoplasms. The individual research proposals involve extensive collaboration and interaction among all of the principal investigators. Studies on DNA repair (Friedberg), molecular genetics (Bowcock/Nisen), proliferation (White), and the folate receptor (Kamen) in brain tumors utilize similar and complementary experimental modalities. A common centralized brain tumor registry, specimen bank and data base core will enable each of the investigators to compare and contrast their observations on the same set of specimens. All brain tumor specimens (pediatric and adult) from the University of Texas Southwestern Medical Center clinical facilities are funneled through Neuropathology (Drs. White and Burns), which will assure appropriate acquisition and standardized evaluation and processing of all necessary samples. Crucial to this proposal is the existence of a large clinical component that will provide a vast amount of patient-derived tumor samples for study, and the ability to optimize existing forms of therapy and allow for rapid application of basic science discoveries to preclinical and clinical trials. The establishment of a Brain Tumor Research Center will facilitate further development of additional research capabilities for basic, applied and clinical research, and specialized clinical training in the care of these patients at the University of Texas Southwestern Medical Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory Grants (P20)
Project #
1P20CA060173-01
Application #
3100601
Study Section
Special Emphasis Panel (SRC (55))
Project Start
1993-03-05
Project End
1996-02-28
Budget Start
1993-03-05
Budget End
1994-02-28
Support Year
1
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Type
Schools of Medicine
DUNS #
City
Dallas
State
TX
Country
United States
Zip Code
75390
Hong, F D; Chen, J; Donovan, S et al. (1999) Taxol, vincristine or nocodazole induces lethality in G1-checkpoint-defective human astrocytoma U373MG cells by triggering hyperploid progression. Carcinogenesis 20:1161-8
Chen, J; Bezdek, T; Chang, J et al. (1998) A glial-specific, repressible, adenovirus vector for brain tumor gene therapy. Cancer Res 58:3504-7
Perry, A; Tonk, V; McIntire, D D et al. (1997) Interphase cytogenetic (in situ hybridization) analysis of astrocytomas using archival, formalin-fixed, paraffin-embedded tissue and nonfluorescent light microscopy. Am J Clin Pathol 108:166-74
Chen, J; Willingham, T; Shuford, M et al. (1996) Effects of ectopic overexpression of p21(WAF1/CIP1) on aneuploidy and the malignant phenotype of human brain tumor cells. Oncogene 13:1395-403
Chen, J; Willingham, T; Shuford, M et al. (1996) Tumor suppression and inhibition of aneuploid cell accumulation in human brain tumor cells by ectopic overexpression of the cyclin-dependent kinase inhibitor p27KIP1. J Clin Invest 97:1983-8
Fink, K L; Rushing, E J; Schold Jr, S C et al. (1996) Infrequency of p53 gene mutations in ependymomas. J Neurooncol 27:111-5
Willis, S A; Nisen, P D (1996) Differential induction of the mitogen-activated protein kinase pathway by bacterial lipopolysaccharide in cultured monocytes and astrocytes. Biochem J 313 ( Pt 2):519-24
Kimberlin, D W; Willis, S A; McCracken Jr, G H et al. (1995) Protein synthesis-dependent induction of interleukin-1 beta by lipopolysaccharide is inhibited by dexamethasone via mRNA destabilization in human astroglial cells. J Clin Immunol 15:199-204
Chen, J; Willingham, T; Margraf, L R et al. (1995) Effects of the MYC oncogene antagonist, MAD, on proliferation, cell cycling and the malignant phenotype of human brain tumour cells. Nat Med 1:638-43
Russell, S J; Ye, Y W; Waber, P G et al. (1995) p53 mutations, O6-alkylguanine DNA alkyltransferase activity, and sensitivity to procarbazine in human brain tumors. Cancer 75:1339-42

Showing the most recent 10 out of 13 publications